• Kane Biotech outlined a 2026 commercial launch plan for revyve, a wound-care product positioned to disrupt biofilms and reduce chronic infections.
• US addressable market estimated at USD 423 million to USD 493 million, including about USD 350 million in chronic wounds.
• Presentation cited sustained antimicrobial activity for up to 7 days without antibiotics, including >4-log reduction in a mature biofilm model.
• Real-world case series across 9 centers in the US and Canada covered about 45 patients, with reported conversion from non-healing to healing.
• Management targets break-even in 2027, citing organic growth and potential international licensing as key value-creation paths.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.